BIOSPHERE MEDICAL : revenue, balance sheet and financial ratios

BIOSPHERE MEDICAL is a French company founded 28 years ago, specialized in the sector Fabrication de matériel médico-chirurgical et dentaire. Based in ROISSY-EN-FRANCE (95700), this company of category PME shows in 2024 a revenue of 20.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - BIOSPHERE MEDICAL (SIREN 418584033)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 20 287 916 € 18 069 114 € 17 194 997 € 15 553 239 € 12 915 508 € 13 511 454 € 12 234 316 € 12 044 813 € 10 140 693 €
Net income 3 743 025 € 3 802 106 € 2 751 005 € 1 982 831 € 1 030 230 € 1 805 982 € 1 549 536 € 1 517 357 € 1 358 868 €
EBITDA 7 546 879 € 6 716 186 € 6 457 794 € 4 901 882 € 3 570 495 € 3 814 961 € 3 245 202 € 3 388 833 € 2 968 999 €
Net margin 18.4% 21.0% 16.0% 12.7% 8.0% 13.4% 12.7% 12.6% 13.4%

Revenue and income statement

In 2024, BIOSPHERE MEDICAL achieves revenue of 20.3 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +9.1%. Vs 2023, growth of +12% (18.1 M€ -> 20.3 M€). After deducting consumption (2.6 M€), gross margin stands at 17.7 M€, i.e. a rate of 87%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 7.5 M€, representing 37.2% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 3.7 M€, i.e. 18.4% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

20 287 916 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

17 714 742 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

7 546 879 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

4 703 874 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

3 743 025 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

37.2%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 81%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 20.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

81.229%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

20.937%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

34.5%

Solvency indicators evolution
BIOSPHERE MEDICAL

Sector positioning

Debt ratio
0.0 2024
2022
2023
2024
Q1: 1.92
Med: 18.86
Q3: 55.42
Excellent

In 2024, the debt ratio of BIOSPHERE MEDICAL (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
81.23% 2024
2022
2023
2024
Q1: 24.8%
Med: 50.27%
Q3: 69.09%
Excellent

In 2024, the financial autonomy of BIOSPHERE MEDICAL (81.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.3 years
Q3: 1.74 years
Excellent

In 2024, the repayment capacity of BIOSPHERE MEDICAL (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 473.55. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.0x. Danger: operating income does not cover interest charges, unsustainable situation.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

473.549

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.003

Liquidity indicators evolution
BIOSPHERE MEDICAL

Sector positioning

Liquidity ratio
473.55 2024
2022
2023
2024
Q1: 159.64
Med: 253.69
Q3: 429.69
Excellent

In 2024, the liquidity ratio of BIOSPHERE MEDICAL (473.55) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
0.0x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.67x
Q3: 4.96x
Average -12 pts over 3 years

In 2024, the interest coverage of BIOSPHERE MEDICAL (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 78 days. Excellent situation: suppliers finance 78 days of the operating cycle (retail model). Inventory turnover is 68 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 457 days of revenue, i.e. 25.7 M€ to permanently finance. Over 2016-2024, WCR increased by +279%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

25 744 351 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

78 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

68 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

457 j

WCR and payment terms evolution
BIOSPHERE MEDICAL

Positioning of BIOSPHERE MEDICAL in its sector

Comparison with sector Fabrication de matériel médico-chirurgical et dentaire

Valuation estimate

Based on 57 transactions of similar company sales (all years), the value of BIOSPHERE MEDICAL is estimated at 13 242 525 € (range 3 054 621€ - 25 104 739€). With an EBITDA of 7 546 879€, the sector multiple of 2.5x is applied. The price/revenue ratio is 0.23x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
57 tx
3054k€ 13242k€ 25104k€
13 242 525 € Range: 3 054 621€ - 25 104 739€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
7 546 879 € × 2.5x
Estimation 19 164 243 €
3 766 474€ - 35 440 845€
Revenue Multiple 30%
20 287 916 € × 0.23x
Estimation 4 601 307 €
2 138 461€ - 9 627 455€
Net Income Multiple 20%
3 743 025 € × 3.0x
Estimation 11 400 058 €
2 649 229€ - 22 480 404€
How is this estimate calculated?

This estimate is based on the analysis of 57 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication de matériel médico-chirurgical et dentaire)

Compare BIOSPHERE MEDICAL with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de matériel médico-chirurgical et dentaire

Frequently asked questions about BIOSPHERE MEDICAL

What is the revenue of BIOSPHERE MEDICAL ?

The revenue of BIOSPHERE MEDICAL in 2024 is 20.3 M€.

Is BIOSPHERE MEDICAL profitable?

Yes, BIOSPHERE MEDICAL generated a net profit of 3.7 M€ in 2024.

Where is the headquarters of BIOSPHERE MEDICAL ?

The headquarters of BIOSPHERE MEDICAL is located in ROISSY-EN-FRANCE (95700), in the department Val-d'Oise.

Where to find the tax return of BIOSPHERE MEDICAL ?

The tax return of BIOSPHERE MEDICAL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does BIOSPHERE MEDICAL operate?

BIOSPHERE MEDICAL operates in the sector Fabrication de matériel médico-chirurgical et dentaire (NAF code 32.50A). See the 'Sector positioning' section above to compare the company with its competitors.